Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has closed its public offering of 8,437,500 Class A common shares at US$1.60 per share, raising US$13.5 million before expenses.
The net proceeds will fund the clinical development of CardiolRx for recurrent pericarditis, as well as general expenses and working capital.
Canaccord Genuity (TSX:CF, LSE:CF) was the sole bookrunner for the offering.